SAN DIEGO, June 24 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announced today that it has been selected for inclusion in the Russell Microcap Index, according to the preliminary list of additions issued by the Russell Investment Group. The 2008 reconstitution of the Russell Indexes will take place after the market close on June 27, 2008.
Annual reconstitution of Russell's U.S. indices captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Russell determines membership for its equity indices primarily by objective market-capitalization rankings and style attributes.
"The addition to the Russell Microcap Index represents another step forward for Cardium. Inclusion in the index offers the potential to broaden our exposure to institutional investors and portfolio managers," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies,
Inc. and the Tissue Repair Company, are medical technology companies
primarily focused on the development, manufacture and sale of innovative
therapeutic products and devices for cardiovascular, ischemic and related
indications. Cardium's lead product candidate, Generx(TM) (alferminogene
tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being
developed for potential use by interventional cardiologists as a one-time
treatment to promote and stimulate the growth of collateral circulation in
the hearts of patients with ischemic conditions such as recurrent
|SOURCE Cardium Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved